Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.

Hauser, Robert A; Barkay, Hadas; Fernandez, Hubert H; Factor, Stewart A; Jimenez-Shahed, Joohi; Gross, Nicholas; Marinelli, Leslie; Wilhelm, Amanda; Alexander, Jessica; Gordon, Mark Forrest; Savola, Juha-Matti; Anderson, Karen E

Hauser, Robert A; Barkay, Hadas; Fernandez, Hubert H; Factor, Stewart A; Jimenez-Shahed, Joohi; Gross, Nicholas; Marinelli, Leslie; Wilhelm, Amanda; Alexander, Jessica; Gordon, Mark Forrest; Savola, Juha-Matti; Anderson, Karen E.

Afiliación

Hauser RA; University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL, United States.
Barkay H; Teva Pharmaceuticals, Netanya, Israel.
Fernandez HH; Cleveland Clinic, Cleveland, OH, United States.
Factor SA; Emory University, Atlanta, GA, United States.
Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Gross N; Teva Pharmaceuticals, West Chester, PA, United States.
Marinelli L; Teva Pharmaceuticals, West Chester, PA, United States.
Wilhelm A; Teva Pharmaceuticals, West Chester, PA, United States.
Alexander J; Teva Pharmaceuticals, West Chester, PA, United States.
Gordon MF; Teva Pharmaceuticals, West Chester, PA, United States.
Savola JM; Teva Pharmaceuticals, Basel, Switzerland.
Anderson KE; Georgetown University, Washington, DC, United States.

Front Neurol ; 13: 773999, 2022.

Article en En | MEDLINE | ID: mdl-35280262

Palabras clave

deutetrabenazine; efficacy; safety; tardive dyskinesia; treatment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Front Neurol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google